Lamictal licensed for bipolar disorder

Depressive episodes are one of the symptoms of bipolar disorder
Depressive episodes are one of the symptoms of bipolar disorder

Lamictal (lamotrigine) has had its licence extended to include the treatment of bipolar disorder. Both the tablets and the orodispersible tablets may be used in the prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes.

The exact mechanism of action of lamotrigine in bipolar disease is unknown, but the anticonvulsant’s interaction with voltage-gated sodium channels is thought to be important.

View Lamictal drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...